Redefining the discovery and development of best-in-class oligonucleotide therapeutics
Our Mission
With OligoCreator®, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
OligoCreator, our AI-empowered drug discovery platform, combines both innovative and proven delivery modalities with the precision and specificity of oligonucleotides.
Global partner of choice for oligonucleotide drug discovery and development programs.
About us
We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator® platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.
Mode of Action
Latest News & Events
Secarna Pharmaceuticals to Present at Upcoming Scientific Conferences
- Secarna to present at upcoming OTS Annual Meeting in Denver and SITC Annual Meeting in Phoenix
- Presentations highlight improved, AI-guided oligonucleotide platform as well as updates on lead program SECN-15
Martinsried (Munich), Germany, October 8, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, will present at the upcoming 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) and the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. Poster presentations will highlight novel findings expected to enhance the AI-powered prediction of oligonucleotide efficacy and safety by Oligofyer™, Secarna’s bioinformatics screening and selection module within its OligoCreator® platform, thereby supporting the identification and characterization of best-in-class oligonucleotide therapeutics. In addition, the Company will present updates on its lead program in development, SECN-15, an ASO targeting Neuropilin-1 (NRP1), a multifaceted target for cancer therapy.
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
- Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-
oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise
Martinsried (Munich), Germany, and Zurich, Switzerland, August 24, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.
Secarna Pharmaceuticals to present new preclinical and translational data on SECN-15 at ASCO 2026
- SECN-15, a potential first-in-class antisense oligonucleotide (ASO), constitutes promising new treatment option for solid tumors
- Preclinical data substantiate enhanced anti-tumor immunity in monotherapy as well as in combination therapy setting with the potential to overcome resistance to checkpoint inhibitors
Martinsried (Munich), Germany, May 27, 2026 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics will present new preclinical and translational data for its proprietary lead program SECN-15, an antisense oligonucleotide (ASO) targeting the transmembrane protein Neuropilin-1 (NRP1), in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 in Chicago, IL, USA, on Saturday, May 30, 2026.
With our AI-empowered OligoCreator® platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.
Konstantin Petropoulos, Ph.D., MBA
CEO